WHO ICTRP trial
Dapagliflozin/Metformin tablet bioequivalence
IRCT20130313012810N54 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20130313012810N54 |
|---|---|
| Public title | Dapagliflozin/Metformin tablet bioequivalence |
| Scientific title | Comparative bioequivalence study of the Dapagliflozin 5 mg/ Metformin HCl 1000 mg Extended-release tablets manufactured by Noavaran Daroui Kimia Company vs Xigduo® tablets manufactured by AstraZeneca Pharmaceutical Company in healthy volunteers |
| Primary sponsor | Noavaran Daroui Kimia |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Bioequivalence study in healthy volunteers. |
| Interventions | Intervention 1: Intervention group 1, which consists of 24 healthy and fasting volunteers, will receive a Dapagliflozin 5 mg/ Metformin 1000 mg tablet manufactured by Noavaran Daroui Kimia Pharmaceutical Company. Intervention 2… |
| Registration date | Mar 29, 2025 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: